Remedium Bio, a Needham, MA-based biotechnology company focused on the development of treatments for large unmet clinical needs, received an investment from LifeSpan Vision Ventures.
The amount of the deal was not disclosed.
The company intends to use the funds to advance its lead candidate, RMD-1202, towards Phase 1 studies.
Led by CEO Frank Luppino, Remedium is a biotechnology company focused on the development of treatments for large unmet clinical needs. To enable this, it developed a gene therapy platform, which enables the delivery of therapeutic genes while allowing for simple post-treatment dose adjustment. The Prometheus™ adjustable gene therapy platform enables replacement of a broad range of subcutaneously administered protein treatments with a single injection, adjustable dose gene therapy. The system has a degree of specificity and remains localized to the site of the subcutaneous injection, offering a safe and durable, single injection alternative, at a fraction of the current protein-based therapeutic treatment cost.
Its pipeline includes disease modifying treatments with efficacy in the fields of endocrinology (weight loss and type 2 diabetes), immunology, neurology, and musculoskeletal diseases.
Commenting on the news, Frank Luppino said: “We are extremely excited to welcome Lifespan Vision Ventures as an investor in Remedium Bio. Our Prometheus™ platform is a significant advance in genetic medicine, one that brings the benefits of gene therapy to large unmet needs affecting how we age. Lifespan, with their strong grounding in the science and experience growing innovative companies, is an ideal partner to support Remedium as we enter an exciting new phase in our evolution.”
FinSMEs
11/09/2024